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Review Pharmacological effects of Salvia miltiorrhiza 
(Danshen) on cerebral infarction
Tsai-Hui Lin1 and Ching-Liang Hsieh*1,2,3
Abstract
Danshen, the dried root of Salvia miltiorrhiza, is a Chinese medicine used to promote blood flow and treat vascular 
disease. The present article reviews the pharmacological effects of Danshen on cerebral infarction and possible 
interactions between Danshen and Western drugs. Danshen may reduce or prolong the development of 
atherosclerosis and may have anti-hypertensive and anti-platelet aggregation effects, which prevent cerebral 
infarction. Danshen may enhance endogenous anti-oxidative enzyme activities such as the expression of endothelial 
nitric oxide synthase and may scavenge oxygen free radicals. Prevention and treatment of cerebral infarction by 
Danshen involves multiple pathways, including anti-atherosclerosis, anti-hypertension, anti-platelet aggregation, anti-
inflammatory and anti-oxidative effects.
Review
Background
Danshen, the dried root of Salvia miltiorrhiza, is used in
Chinese medicine to treat vascular disease. According to
Chinese medicine theory, Danshen promotes blood flow
and resolves blood stasis. Among stroke patients, 80%
suffer from cerebral infarction and 20% cerebral hemor-
rhage [1]. Cerebral infarction is an ischemic condition of
the brain including thrombosis, embolism or systemic
hemodynamic hypotension. Cerebral infarction is often
caused by atherosclerosis of large and small arteries. The
etiology of atherosclerosis and stroke is related to inflam-
mation and genetic factors. Ischemic cerebral infarction
may be prevented through anti-inflammation and treat-
ment for vascular diseases, heart diseases and hyperten-
sion [2-4]. Anti-thrombosis and thrombolysis are used to
treat ischemic cerebral infarction [2]. The most effective
m e t h o d  t o  r e - e s t a b l i s h  c e r e b r a l  b l o o d  f l o w  i s  t h r o m -
bolytic therapy; however, this therapy is often at the risk
of bleeding [2]. Neuroprotection is also a potential treat-
ment [5].
While Danshen or its ingredients reduce the infarction
volume, the action mechanism of Danshen  remains
obscure [6-8]. Danshen contains the lipid-soluble tanshi-
none I (Tan I), tanshinone IIA (Tan IIA), cryptotanshi-
none and dihydrotan-shinone as well as the water-soluble
danshensu and salvianolic acid B (Sal B) [9]. Danshen
inhibits platelet aggregation and promotes fibrinolysis
[10,11].
Covering literature between 1990 and 2009, this article
reviews basic and clinical studies on Danshen in the pre-
vention and treatment for cerebral infarction. The key
words used for search in the PubMed library were 'Dan-
shen' or 'Salvia miltiorrhiza' combined with 'cerebral
infarction', 'ischemic' or 'cerebral ischemia'.
Prevention of cerebral infarction
Anti-atherosclerosis and anti-inflammatory effects
Atherosclerosis is caused by endothelial damage, which
may lead to platelet aggregation and the release of platelet
factor, resulting in the proliferation of smooth muscle in
the arterial intima. The process of atherosclerosis com-
prises inflammation and involves both innate and adap-
tive immunity [12]. The tanshinones components of
Danshen (tanshinone I, dihydrotanshinone and crypto-
tanshinone) inhibit the production of interleukin-12 (IL-
12) induced by lipopolysaccharide (LPS)-activated mac-
rophages and the production of interferon-γ induced by
keyhole limpet hemocyanin-primed lymph node cells
[13]. Tanshinones also inhibit the expression of the IL-12
p40 gene and prevent nuclear factor-κB (NF-κB) from
binding to κB site [13]. As IL-12 and NF-κB are closely
associated with inflammatory responses, tanshinones
may have anti-inflammatory effects [13]. Tumor necrosis
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factor-α (TNF-α), a pro-inflammatory cytokine, is regu-
lated by NF-κB while vascular adhesion molecule-1
(VCAM-1) regulates the migration of leukocytes into the
vessel wall. Pre-treatment with either aqueous ethanolic
extract of Danshen or Sal B component of Danshen inhib-
its TNF-α-induced expression of VCAM-1 and TNF-α-
induced activation of NF-κB in human aortic endothelial
cells, suggesting that both SME and Sal B posses anti-
inflammatory properties and are closely associated with
atherogenesis because leukocytes migrate into the vessel
wall in the early stage of atherogenesis [14]. Aqueous
extract of Danshen suppresses the adhesion rate of neu-
trophils stimulated by TNF-α, and also inhibits adhesion
of neutrophils stimulated by N-formyl-methionyl-leucyl-
phenylalanine (fMLP) [15]. Aqueous extract of Danshen
inhibits TNF-α-induced up-regulation of E-selectin,
intracellular molecule-1 (ICAM-1) and VCAM-1 expres-
sion [15]. Danshen  treatment lowers plasma viscosity,
erythrocyte aggregation and fibrinogen levels in rats with
traumatic brain injury [16]. Tan IIA increases estrogen
receptor activity in HeLa cells. Tan IIA inhibits iNOS
(inducible nitric oxide synthase) protein production and
nitric oxide (NO) production and inhibits pro-inflamma-
tory cytokine IL-1β, IL-6 and TNF-α via estrogen recep-
tors in lipopolysaccharide (LPS) activated RAW 264.7
macrophages, suggesting that Tan IIA may serve as an
estrogen-receptor-like modulator to produce immune
responses [17]. C-reactive protein (CRP), an inflamma-
tion marker, induces pro-inflammatory cytokines
through NF-κB and contributes to atherosclerosis in
endothelial cells [18,19]. Tan IIA inhibits NF-κB-DNA
complex, NF-κB binding activity and the phosphorylation
of IκBα and inhibit the translocation of NF-κB from cyto-
sol to nuclei, demonstrating that tanshinone possesses
anti-inflammatory properties [20]. Tan IIA down-regu-
lates protein expression and activities of matrix metallo-
proteinase-2 and -9 (MMP-2, MMP-9) and reduces the
VCAM-1 and IL-1β levels to suppress the increase in the
aorta intimal area in rabbits treated with a high-fat-diet
[21]. Triterpenoids-enriched extract of Danshen reduces
the aortic atherosclerotic lesion area and inhibits inflam-
matory serum marker of CRP and monocyte chemotactic
protein (MCP-1) [22]. Moreover, triterpenoids-enriched
extract of Danshen reduces the serum levels of total cho-
lesterol and triglyceride in low density lipoprotein recep-
tor (LDLR) +mice via the inhibition of the inflammatory
markers CRP and MCP-1 [22]. Triterpenoids are anti-
atherogenic which may be associated with its anti-inflam-
matory properties [22]. In summary, the anti-atheroscle-
rosis and anti-inflammatory actions of Danshen play roles
in the prevention of cerebral infarction.
Anti-hypertensive effects
Hypertension is a risk factor for cerebral infarction.
Maintaining blood pressure within the ideal range has
recently been recognized as an important principle in the
prevention and treatment of ischemic cerebral infarction.
Aqueous extract of Danshen alleviates hypertension in
the two-kidney/one-clip (2K1C) Goldblatt renovascular
hypertensive rats model and reduced the activity of
serum angiotensin converting enzyme and the levels of
serum aldosterone [23,24]. MTB70 is composed of 70%
(70 mg/ml) of Magnesium tanshinoate B (MTB) which is
one of the aqueous active components of Danshen.
MTB70 (0.7-175 mg/kg) reduces blood pressure more
than the aqueous extract of Danshen with same volume in
a saline- or phenylephrine (2.5 μg/kg bolus injection and
followed by 100 μg/kg at 0.13 ml/hr injection continu-
ously) -induced hypertension model in rats; However this
rapid and potent anti-hypertensive effect is short-lived
[25]. Tanshinone IIA reduces blood pressure in the 2K1C
renovascular hypertension model of hamsters [26]. Over-
all, the anti-hypertensive effects of Danshen include inhi-
bition of angiotensin converting enzyme and generation
of eNOS and/or vasodilatation.
Treatment of cerebral infarction
Anti-platelet aggregation effects
Anti-platelet aggregation, which involves platelet adhe-
sion, is widely used to treat acute ischemic cerebral
infarction [27]. Platelet adhesion increases in mice with
middle cerebral artery occlusion (MCAo) [28]. Eight
derivatives of Danshen  inhibit platelet aggregation
induced by adenosine diphosphate (ADP) in vitro in rab-
bit plasma [29]. Salvianolic acid B (SAB) inhibits platelet
deposition to collagen at venous and arterial shear rates,
suggesting that SAB inhibits platelet adhesion to collagen
via interfering collagen receptor α2β1 [30]. Salvianolic
acid inhibits ADP-induced platelet aggregation in plate-
let-rich plasma and in washed platelets both in vivo and
in vitro, probably through changing protein expression
[31].  Danshen  decreases the malondialdehyde (MDA)
levels of platelets and increases the superoxide dismutase
(SOD) activity of platelets to inhibit platelet aggregation
in pulmonary thromboembolism induced by collagen and
adrenaline in mice [32]. The 764-3 (100 μg/ml), purified
compound of Danshen extract, inhibits platelet aggrega-
tion induced by arachidonic acid or ADP in humans and
rabbits [33]. Danshen  decreases the concentration of
intra-platelet free calcium, which is closely associated
with platelet aggregation and release [34]. Overall, Dan-
shen exhibits anti-platelet aggregation effects via multiple
pathways, e.g. the inhibition of intra-platelet calcium and
anti-oxidant activities.
Neuroprotection through anti-inflammatory effects
Inflammatory responses are critically important to a
patient after brain ischemia/reperfusion injury. The pro-
inflammatory cytokines IL-1β, TNF-α and IL-6 increase
after an ischemia attack, which enhances the expressionLin and Hsieh Chinese Medicine 2010, 5:22
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of adhesion molecules including ICAM-1 and P-selectin,
leading to brain edema and neuronal death [35,36]. In
addition, leukocytes, neurons and activated microglial
cells in ischemic damaged region release cytokines,
chemokines and oxygen free radicals which lead to sec-
ondary brain tissue damage. Matrix metalloproteinases,
which cleave protein components of the extracellular
matrix, play a role in neurovascular remodeling and neu-
ronal death [35,36]. The microglia may be activated dur-
ing brain damage including ischemia, inflammation and
infection [37]. The increases of activated microglia may
represent the severity of neuronal damage in a MCAo rat
model [38]. Danshen inhibits superoxide generation by
microglia in primary microglia cell cultures from rat
brains [39]. Danshen reduces CD18 and CD11b immuno-
reactive cells in the peri-vascular region and inhibits leu-
kocyte infiltration and neuronal death in the cerebral
infarction region in the ischemia-reperfusion MCAo rat
model. As leukocytes are mediated via the combination
of surface receptors of CD18 and CD11b and intracellular
adhesion molecules of endothelium, the neuroprotection
capability of Danshen may be associated with the inhibi-
tion of leukocyte adherence to the endothelium [40]. A
study on the effects of Danshen  on inflammatory
response in cerebral ischemia and reperfusion injury in
the MCAo rat model indicates that pre-treatment with
Tanshinone IIA reduces the cerebral infarction area, neu-
rological deficit score and cerebral edema. As pre-treat-
ment with Tanshinone IIA reduces TNF-α, the
myeloperoxidase (MPO) marker of leukocytes, E-selectin
and ICAM-1 in ischemic brain tissue and serum IL-8,
Danshen may inhibit inflammatory responses to reduce
brain damage induced by ischemia-reperfusion injury in
rats [41]. The Danshen dripping pill (DDP) is composed
of Danshen, Panax notoginseng and Dryobalanops cam-
phor. A controlled pilot study (106 patients) found that
the recurrent rate in the DDP group was 9.6% compared
with 24.1% in the non-DDP group. The serum CRP levels
decreased from 2.33 to 1.50 mg/L in the DPP group were
greater than those decreased from 2.21 to 1.77 mg/L in
the non-DDP group [42]. Overall, Danshen  has anti-
inflammatory activity and may improve cerebral infarc-
tion and provide neuroprotection.
Neuroprotection through anti-oxidative effects
Nitrogen and oxygen free radicals involved in the produc-
tion of reactive oxygen species (ROS) play an important
role in brain damage during the reperfusion period fol-
lowing ischemia [43,44]. These ROS, which are involved
in brain damage after cerebral ischemia, affect the signal
transmission of mitochondria and DNA repair of enzyme
and transcription factors, leading to apoptosis [45]. Dan-
shensu and salvianolic acid B are phenolic acids of Dan-
shen, both of which have scavenging activities towards
free radicals of hydroxyl, 1,1-diphenyl-2-picryl-hydrazyl
(DPPH), 2-azino-bis(3-ehtylbenzthiazoline-6-sulfonic
acid) (ABTS) free radicals, hydrogen peroxidase and
superoxide anion in human umbilical vein endothelial
cells [46]. Our previous studies show that Danshen
reduces the cerebral infarction volume and the neurologi-
cal deficit score and reduces luminal-chemiluminescence
counts [8]. As luminal-chemiluminescence counts may
represent ROS, these effects of Danshen may be associ-
ated with its free radical scavenging activities in isch-
emia-reperfusion injured rats [8]. Intra-abdominal
administration of Tan IIB, a major active component of
Danshen, reduces the focal infarct volume, neurological
deficit and apoptosis in the MCAo rat model. As apopto-
sis is a major pathway leading to neuronal death, Tan IIB
is neuroprotective [47]. Damage from oxygen free radi-
cals occurs in the ischemic/reperfusion injury under oxi-
dation response to cell membrane lipids, proteins or
DNA. Inhibiting oxidation and free radical scavenging are
important in the treatment of ischemic cerebral infarc-
tion. A study using a 4-vessel occlusion rat model [48,49]
found that (1) Danshen reduced an increase of cerebral
NO and MDA 30 minutes prior to occlusion and that (2)
pre-treatment with Danshen  increased a significantly
decreased SOD activity. NO mediates glutamate neuro-
toxicity and the inhibition of NO synthase may prevent
the development of brain edema. SOD is a scavenger of
superoxide anion and the levels of MDA may reflect the
degree of lipid peroxidation. Thus Danshen is neuropro-
tective in this occlusion and reperfusion rat model
[48,49]. Isopropyl-β,-(3,4-dihydroxyphenyl)-α-hydroxy-
propanoate (ND-309), a metabolite of Danshen  in rat
brain, reduces cerebral infarction volume, brain edema
and neurological deficit in the MCAo rat model. More-
over, ND309 reduces brain tissue MDA and increases the
reduction of ATP induced by ischemia-reperfusion injury
[50] of mitochondrial ATP, mitochondrial SOD and glu-
tathione peroxidase (GSH-Px) activities induced by isch-
emia-reperfusion injury. ND-309 is neuroprotective role
to reduce brain damage induced by cerebral ischemia
[50]. Danshen reduces the neurological deficit score and
the levels of MDA and increases SOD activities in the
MCAo rat model [51]. Pretreatment with Danshen may
reduce brain edema and MDA concentration of cerebral
cortex and hippocampus region in an ischemia-reperfu-
sion injured rat model while Danshen may increase levels
of catalase, SOD, GSH and ATP of the cerebral cortex and
hippocampus region [52]. In summary, Danshen demon-
strates neuroprotective effects that are closely associated
with anti-oxidative action.
Drug interactions with warfarin
Warfarin is an anticoagulant used to prevent atrial fibril-
lation, valvular heart disease, ischemic stroke and deep
venous thrombosis [53]. Danshen inhibits platelet adhe-Lin and Hsieh Chinese Medicine 2010, 5:22
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sion and aggregation and suppresses the formation of
thromboxane A 2 [53]. The interaction between Danshen
and warfarin can cause bleeding and prolong prothrom-
bin time or the International Normalized Ratio (INR)
[53]. Co-administration of Danshen and warfarin should
be avoided or closely monitored [54]. Tanshinones inhib-
its CYP1A1, CYP2C6 and CYP2C11-mediated warfarin
metabolism to increase the concentration of warfarin
[55]. Aspirin prevents and alleviates cerebral infarction.
Danshen displaces the binding between aspirin and pro-
tein, thereby increasing free aspirin concentration in
serum [56]. Atrial fibrillation, which may be prevented
and treated by digoxin, is closely related to cerebral
infarction induced by embolus. Danshen has digoxin-like
immunoreactivity leading to a false interference of
digoxin concentration [56].
Compared free radical scavenging ability with other herbs
The extracts of Ginkgo biloba L. leaves (Egb 761), with
free radical scavenging activity, reduce the size of cerebral
infarction and improve neurological behavior in rats with
permanent and transient MCAo [57,58]. Egb 761 is
widely used to treat ischemic cerebral infarction. The
concentration of salvianolic acid B is lower than Egb 761
in scavenging activity of superoxide anion and hydroxyl
radicals in rat microsome, and in SH-SY5Y induced by H
2O 2 [59]. Panax notoginseng (Sanqi) is also used to treat
vascular disorders. Danshen is stronger than Panax noto-
ginseng  in scavenging activity of superoxide anion,
hydroxyl and DPPH radicals, yet it is weaker than Panax
notoginseng in the scavenging activity of hydrogen perox-
ide and ferrous ion chelating activity [60]. While Sanqi
demonstrates strong ferrous ion chelating activity and
s t r o n g  s c a v e n g i n g  a c t i v i t i e s  o f  h y d r o g e n  p e r o x i d e  a n d
hydroxyl radicals, it is weak in the scavenging activities of
superoxide anion and DPPH radicals. Therefore, the
scavenging capabilities of Danshen and Sanqi are quite
different among the various free radicals [60].
Conclusion
Prevention and treatment of cerebral infarction by Dan-
shen  involves multiple pathways, including anti-athero-
sclerosis, anti-hypertension, anti-platelet aggregation,
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